December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Ramsay McFarlane

CEO
Awen Oncology

Dr McFarlane is a cancer geneticist working in both academia and industry. He received his PhD in molecular genetics under Prof. John Saunders at the University of Liverpool, followed by postdoctoral positions working on cell cycle regulation and genome stability at the Krebs Institute, University of Sheffield, under Sir Paul Nurse and Prof. Dave Hornby, and at the Fred Hutchinson Cancer Research Centre in Seattle with Dr Gerry Smith. He was then appointed to an academic position at Bangor University, where he founded the North West Cancer Research Institute and served as Director of Research for the new Medical School. A sabbatical at the CABIMER Regenerative Medicine Institute in Seville inspired him to commercialise his work to bring real-world benefits to patients. To that end, in 2021 he established Awen Oncology with co-founders Dr Jane Wakeman and Professor Andrea Brancale (then at Cardiff University), backed by investment from the Cambridge Innovation Capital Start Codon programme, the Development Bank of Wales and the Spitz family office, and grants from Cancer Research UK, Innovate UK, o2h Discovery and the Welsh Government. Awen Oncology is an Affiliate of the University of Cambridge Milner Therapeutics Institute and is based at M-SParc, the new science park on Anglesey, where the team is developing novel small molecule therapeutics for a range of cancers, including the rare bone cancer chordoma.

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.